PMID- 32482023
OWN - NLM
STAT- MEDLINE
DCOM- 20200630
LR  - 20211204
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 42
IP  - 5
DP  - 2020 May 23
TI  - [New advances in targeted therapy for breast cancer].
PG  - 353-361
LID - 10.3760/cma.j.cn112152-112152-20190919-00614 [doi]
AB  - Objective: Breast cancer is a kind of malignant tumor which seriously endangers 
      women's health. With the development of molecular biology technology and the 
      further understanding of pathogenesis, the treatment of breast cancer has entered 
      a new era of molecular targeted therapy, and has been making new progress. At 
      present, molecular targeted drugs for the treatment of breast cancer keep 
      emerging, mainly including endocrine therapy targeting estrogen and progesterone 
      receptor (ER/PR), targeted drugs treatment for epidermal growth factor receptor-2 
      (HER-2); phosphatidylinositol 3 kinase (PI3K)/Akt/mammalian target of rapamycin 
      (mTOR) pathway inhibitors, anti-angiogenic drugs, poly (ADP-ribose) polymerase 
      (PARP) inhibitors for BRCA1/2 mutations, cyclin-dependent kinases (CDK) 4/6 
      inhibitors, etc. Because some signal pathway abnormalities may occur in different 
      molecular types of breast cancer, the same targeted drugs are cross-used in 
      different types.
FAU - Zhao, J
AU  - Zhao J
AD  - Department of Breast Oncology, Tianjin Medical University Cancer Institute and 
      Hospital/National Clinical Center for Cancer/Key Laboratory of Cancer Prevention 
      and Therapy, Tianjin/Tianjin's Clinical Research Center for Cancer/Key Laboratory 
      of Prevention and Therapy, Tianjin Medical University, Ministry of Education, 
      Tianjin 300060, China.
FAU - Wu, N
AU  - Wu N
AD  - Department of Cancer Prevention Center, Tianjin Medical University Cancer 
      Institute and Hospital/National Clinical Center for Cancer/Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin/Tianjin's Clinical Research Center for 
      Cancer/Key Laboratory of Prevention and Therapy, Tianjin Medical University, 
      Ministry of Education, Tianjin 300060, China.
FAU - Zhang, S C
AU  - Zhang SC
AD  - Department of Breast Oncology, Tianjin Medical University Cancer Institute and 
      Hospital/National Clinical Center for Cancer/Key Laboratory of Cancer Prevention 
      and Therapy, Tianjin/Tianjin's Clinical Research Center for Cancer/Key Laboratory 
      of Prevention and Therapy, Tianjin Medical University, Ministry of Education, 
      Tianjin 300060, China.
FAU - Zhao, Z W
AU  - Zhao ZW
AD  - Department of Breast Oncology, Tianjin Medical University Cancer Institute and 
      Hospital/National Clinical Center for Cancer/Key Laboratory of Cancer Prevention 
      and Therapy, Tianjin/Tianjin's Clinical Research Center for Cancer/Key Laboratory 
      of Prevention and Therapy, Tianjin Medical University, Ministry of Education, 
      Tianjin 300060, China.
FAU - Li, L J
AU  - Li LJ
AD  - Department of Cancer Prevention Center, Tianjin Medical University Cancer 
      Institute and Hospital/National Clinical Center for Cancer/Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin/Tianjin's Clinical Research Center for 
      Cancer/Key Laboratory of Prevention and Therapy, Tianjin Medical University, 
      Ministry of Education, Tianjin 300060, China.
FAU - Liu, J T
AU  - Liu JT
AD  - Department of Cancer Prevention Center, Tianjin Medical University Cancer 
      Institute and Hospital/National Clinical Center for Cancer/Key Laboratory of 
      Cancer Prevention and Therapy, Tianjin/Tianjin's Clinical Research Center for 
      Cancer/Key Laboratory of Prevention and Therapy, Tianjin Medical University, 
      Ministry of Education, Tianjin 300060, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Receptors, Estrogen)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antineoplastic Agents/*administration & dosage
MH  - Breast Neoplasms/*drug therapy/pathology
MH  - Female
MH  - Humans
MH  - *Molecular Targeted Therapy
MH  - Phosphatidylinositol 3-Kinases
MH  - Proto-Oncogene Proteins c-akt
MH  - Receptor, ErbB-2/metabolism
MH  - Receptors, Estrogen
MH  - TOR Serine-Threonine Kinases/metabolism
OTO - NOTNLM
OT  - Breast neoplasms
OT  - Development
OT  - Molecular subtype
OT  - Targeted therapy
EDAT- 2020/06/03 06:00
MHDA- 2020/07/01 06:00
CRDT- 2020/06/03 06:00
PHST- 2020/06/03 06:00 [entrez]
PHST- 2020/06/03 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
AID - 10.3760/cma.j.cn112152-112152-20190919-00614 [doi]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 2020 May 23;42(5):353-361. doi: 
      10.3760/cma.j.cn112152-112152-20190919-00614.